L iver disease is a clinical priority area identified by the RCGP, due to increasing levels of morbidity and mortality. Liver disease causes an estimated 8500 premature deaths in the UK annually, predominantly from a rise in non-alcoholic fatty liver disease, alcoholrelated liver disease, and viral hepatitis. There has been a corresponding increase in liver function tests (LFTs) ordered from primary care, often as part of medication reviews or monitoring of chronic disease. GPs will therefore encounter an increasing number of abnormal LFTs in patients asymptomatic of liver disease. This article outlines a framework for investigating abnormal LFTs in primary care.
The GP curriculum and abnormal liver function tests Clinical module 3.13: Digestive health lists the learning objectives required for a GP to manage abnormal liver function tests. In particular, GPs are expected to be able to: . Understand the epidemiology of digestive problems as they present in primary care and their often complex aetiology . Know how to interpret common symptoms in general practice, including abdominal pain, nausea, vomiting, anorexia, jaundice
. Demonstrate a systematic approach to investigating common digestive problems, taking into account the prevalence of these symptoms in primary care and the likelihood of conditions such as hepatitis
. Be familiar with contemporary developments around drug treatment options for hepatitis B and C Liver function tests: What are they and why do we check them?
The standard panel of liver function tests (LFTs) varies from one hospital to another, but may include measurement of bilirubin, albumin, aspartate transaminase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), and alkaline phosphatase (ALP) (Hamilton and Bickle, 2012) . Although not entirely specific for liver disease, AST and ALT are broadly considered as markers of hepatocyte injury, whereas elevations in ALP and GGT may arise from cholestasis, which is obstruction of the biliary tract (Friedman, 2018) . The synthetic function of the liver is assessed by serum albumin and prothrombin time (PT). GPs may request LFTs due to a clinical suspicion of liver disease. New guidelines from the British Society of Gastroenterology advise that initial investigations should include bilirubin, albumin, ALT, ALP, GGT, and a full blood count (FBC) if not already performed within the previous year (Box 1) (Newsome et al., 2018) . However, it is more common for GPs to request LFTs as part of either non-specific routine bloods, medication reviews, or for monitoring chronic diseases such as hypertension, hyperlipidemia, or diabetes in patients asymptomatic of liver disease (Armstrong et al., 2012) . Hence, abnormal LFTs may often be of uncertain clinical significance.
Investigating abnormal LFTs

Why should we investigate?
A retrospective cohort study on data from 1989 to 2003 showed that over 50% of patients with abnormal LFTs in primary care were not further investigated (Donnan et al., 2009 ). This represents a missed opportunity for intervention, not only because the diagnosis of liver disease has been shown to motivate a subset of patients to take ownership of their condition and change relevant lifestyle and behavioural factors (Lilford et al., 2013) , but also because the majority of patients who present with acute liver decompensation have previously had abnormal LFTs. The National Institute for Health and Care Excellence (NICE) has a 3% positive predictive value (PPV) threshold for new urgent suspected cancer referrals. In the context of newer studies demonstrating LFTs including ALP and ALT have a 7% PPV of liver disease (Lilford et al., 2013) , and that 2% of patients with abnormal LFTs in primary care have underlying liver fibrosis (Armstrong et al., 2012) , investigations for abnormal LFTs within primary care should be strongly considered.
The degree of abnormality does not always reflect the extent of the liver disease With the exception of an AST or ALT level above 300 IU/L, where the high probability of acute viral hepatitis and acute toxic or ischemic injury should prompt urgent referral for management, the degree of abnormality in transaminases does not indicate the severity of the liver disease. The degree of abnormality in LFTs is also not indicative of the potential for fibrosis (Newsome et al., 2018) . Studies have shown that patients with alcohol-related liver disease (ARLD), non-alcoholic fatty liver disease (NAFLD), and chronic hepatitis may have mild or moderate abnormalities, whereas patients with significant liver fibrosis may have entirely normal LFTs ( Fig. 1) (Jarvis and Hanratty, 2017) . This again emphasises the need to interpret LFTs in clinical context.
Abnormal LFTs are likely to remain abnormal
In the Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS) prospective cohort study, 84% of abnormal LFTs found in primary care remained abnormal on retesting a month later. Even at 2 years, 75% of LFTs remained abnormal (Lilford et al., 2013) . Re-testing is thus neither clinically effective nor cost-effective. Unless a transient cause is suspected, patients with abnormal LFTs should undergo a liver aetiology screen regardless of the level and duration of abnormality (Newsome et al., 2018) . Aminotransferases in cirrhosis and NAFLD can be normal (Fracanzani et al., 2008; Johnston, 1999; Kasarala and Tillmann, 2016) . The upper limit of normal (ULN) for both AST and ALT are 35 U/L, with some variability between laboratories. Levels above 300 U/L should prompt consideration of acute viral hepatitis or toxic or ischemic injury. 
Always interpret LFTs in clinical context
LFTs should always be interpreted with reference to previous results, and in clinical context (Newsome et al., 2018) . One should always take a thorough clinical history and perform a clinical examination for risk factors, symptoms and signs suggestive of liver disease (Box 2). For example, the finding of mildly elevated transaminases may be an expected finding in a patient that has newly commenced on statins, but may represent end-stage ARLD in a patient with a history of harmful drinking. A clinical history of intravenous drug use or immigration from areas of high prevalence is also more predictive of the likelihood of viral hepatitis than derangements in LFTs.
The clinical pattern and the liver aetiology screen Abnormalities in LFTs can be broadly subdivided into four common patterns (Box 3), which then guide further investigations as recommended by the British Society of Gastroenterology's new guidelines ( Figure 2 ) (Newsome et al., 2018) .
Patients with abnormal LFTs should be considered for investigation with a standard liver aetiology screen (Table 1) and liver ultrasound as advised by new guidelines (Figure 2 ). It differs from the British Medical Ultrasound Society (BMUS) guideline in 2015, which specifically advised against an abdominal ultrasound for a single episode of raised ALT (BMUS Professional Standard Group, 2015) . This change reflects findings from the previously discussed BALLETS study, which demonstrated abnormal LFTs are likely to remain abnormal (Lilford et al., 2013) .
The extended liver aetiology screen may be undertaken in patients with no clear cause (Newsome et al., 2018) . Patients with results suggestive of viral hepatitis, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, or hemochromatosis should be referred to hepatology. If the extended liver aetiology screen is normal, and there is no suspicion of NAFLD or ARLD, patients should be referred or discussed with a hepatologist for further assessment (Newsome et al., 2018) .
The AST:ALT ratio
The AST:ALT ratio, also known as the De Ritis ratio, has historically been used as a crude indicator of the aetiology and prognosis of liver disease. There is no agreed healthy limit for the ratio, and there is variation between genders, but broadly a Box 3. Patterns of LFT abnormalities.
Isolated raised bilirubin
The most common cause of a raised bilirubin in isolation is Gilbert's disease, which affects 5 -8% of the population. This can be confirmed by a split bilirubin, which will show a mild elevation in unconjugated bilirubin. A FBC should be performed to exclude anemia. If the patient is anemic, a reticulocyte count, lactate dehydrogenase, and haptoglobin should be requested to exclude hemolysis Cholestasis Biliary obstruction is suggested by elevations in ALP and GGT. Transaminases may also be raised to a lesser degree in cholestasis due to back pressure on the liver (Hamilton and Bickle, 2012) . Examples of diseases causing cholestasis include choledocholithiasis, primary biliary cirrhosis, primary sclerosing cholangitis, biliary strictures, and malignancy. If the ALP is elevated in isolation, consider a bone aetiology. An elevation in GGT is not specific to detecting alcohol misuse, but is predictive of mortality (Newsome et al., 2018) . Therefore, a raised GGT in the absence of a suspicious alcohol history should prompt further investigations Hepatocellular A transaminitis including elevations of AST and/or ALT is suggestive of hepatocellular damage. A liver aetiology screen should be performed to exclude common causes including NAFLD, viral hepatitis, ARLD, and auto-immune liver disease
Hepatic dysfunction A prolonged PT or reduced serum albumin should prompt consideration of synthetic failure Box 2. Clinical history and examination for liver disease.
Clinical history
. Symptoms of liver disease (e.g. jaundice, pruritus, abdominal pain, bruising, weight loss, fatigue, confusion)
. Risk factors for metabolic syndrome (e.g. hypertension, diabetes, dyslipidemia)
. Drug history (e.g. prescription, over the counter, herbal, recreational)
. Family history (e.g. country of birth, inherited liver diseases)
. Spider naevi/caput medusae Gynaecomastia Peripheral stigmata (e.g. bruising, Dupuytren's contracture, palmar erythema) ratio > 1.0 is suggestive of fibrosis or cirrhosis, and a ratio > 2.0 in the context of a raised GGT is suggestive of alcoholic hepatitis (Botros and Sikaris, 2013) . The AST:ALT ratio is not included in the new guidelines on the investigation of abnormal LFTs, as its use has been superseded by other ratios, such as the AST to Platelet Ratio Index and the Fibrosis-4 (FIB4) indices, which are more predictive of fibrosis (Botros and Sikaris, 2013) .
The approach to common liver conditions
Non-alcoholic fatty liver disease
The most common cause of incidental abnormal LFTs in primary care is NAFLD; it affects an estimated 20 to 30% of the UK adult population (NICE, 2016) , and ranges histologically from non-alcoholic fatty liver (NAFL), a relatively benign condition characterised by steatosis with no or minor inflammation, to non-alcoholic steatohepatitis (NASH), where ballooning and inflammation is present with or without progression to liver fibrosis and cirrhosis. Studies estimate that 30% of patients with NAFL go on to develop NASH, of which around 20% will develop liver fibrosis (DeWeerdt, 2017) . The progression of fibrosis is not absolute. In followup studies, 33.6% had fibrosis progression, 43.1% had stable fibrosis, and 22.3% had an improvement in fibrosis stage. Fibrosis progression is also characteristically slow, taking an average of 7.7 years to progress one stage (Singh et al., 2015) . In patients without a history of harmful alcohol use, but who have raised transaminases and a normal liver aetiology screen, the diagnosis of NAFLD should be considered. Hepatic steatosis may be diagnosed on liver ultrasound by increased liver echogenicity. However, liver ultrasound is only sensitive for steatosis when more then 30% of hepatocytes are steatotic (Lee and Park, 2014) . Therefore, the diagnosis of NAFLD should be considered even in individuals with a normal ultrasound if they have risk factors for NAFLD, such as metabolic syndrome. Patients with NAFLD need to be assessed for fibrosis. New guidelines recommend first-line testing with the FIB4 index or NAFLD Fibrosis Score (NFS) InnovAiT (Box 4) (Newsome et al., 2018) . Individuals with a low risk of fibrosis should be managed in primary care. GPs should assess patients' cardiovascular risk, managing co-morbid diabetes, hypertension, and dyslipidemia. In patients who are overweight, lifestyle intervention for weight loss should also be offered. Their risk of fibrosis should be re-assessed every 2 to 5 years. Patients with indeterminate FIB4 or NFS scores should proceed onwards to second-line testing with either the Fibroscan or serum enhanced liver fibrosis (ELF) measurement (Fig. 2) (Box 5). Any patient with a high risk of advanced fibrosis should be referred to hepatology for further assessment and management, where screening for portal hypertension and hepatocellular carcinoma will be organised if necessary (Newsome et al., 2018) .
Alcohol-related liver disease
Over 25% of the population in the UK drinks more than the recommended limit of 14 units per week (Lilford et al., 2013) . With there being a direct relationship between alcohol consumption and liver cirrhosis, it is unsurprising that alcoholrelated cirrhosis is the leading cause of liver-related mortality in Western populations (Newsome et al., 2018) .
Individuals with suspected ARLD should be assessed using the Alcohol Use Disorders Identification Test (AUDIT). New guidelines recommend that any individual with a history of harmful drinking, that is greater than 50 units/week for men and 35 units/week for women, or an AUDIT score greater than 19 should be offered either an ELF test or Fibroscan to detect advanced fibrosis (Fig. 2) (Newsome et al., 2018) . All patients with ARLD should be advised to abstain from alcohol, and offered either alcohol advice or referral to alcohol services. Patients with possible advanced liver fibrosis who continue drinking, and anyone with suspected cirrhosis should be referred to hepatology for ongoing management (Newsome et al., 2018) .
Viral hepatitis
Patients with acute viral hepatitis may present with nausea, fatigue, and jaundice, and be found to have a severe transaminitis. Hepatitis serology may be used to differentiate between acute and chronic infections ( Table 2 ). Hepatitis A and hepatitis E viruses, transmitted through the fecal-oral route, typically self-resolve, whereas a percentage of individuals with hepatitis B virus (HBV) and hepatitis C virus (HCV) will have a persisting mild elevation of transaminases secondary to the development of a chronic infection.
HBV can be transmitted both horizontally, such as through sex with an infected partner or by sharing needles, as well as vertically from mother to child perinatally. An estimated 400 000 000 people worldwide, primarily in South America, Africa, Russia, and Asia, have a chronic HBV infection, which is associated with a 15 to 40% lifetime risk of developing cirrhosis. A positive hepatitis B surface antigen (HBsAg) indicates current infection, with the hepatitis B e antigen (HBeAg) serving as a marker of a high degree of infectivity. The presence of hepatitis B surface antibody (anti-HBs) demonstrates immunity from HBV infection, either from vaccination or recovery from prior infection. Co-infection with hepatitis D should be considered. Chronic HBV infection should be managed in secondary care. The treatment algorithm recommended by NICE is complex and beyond the scope of this review, but broadly, patients with a high viral load or evidence of fibrosis are commenced first-line on pegylated-interferon-a2a. The seroconversion rates, however, are low and the majority of individuals will require long-term viral suppression with tenofovir or entecavir (Tang et al., 2014) .
HCV is transmitted parenterally, historically through blood transfusions but now more commonly through intravenous drug use. The majority develop a chronic HCV infection (Chopra, 2018) . On testing, the finding of a positive HCV antibody should be followed by measurement of the viral load to establish whether there is a current infection. Chronic HCV infection should likewise be managed in secondary care. The management of HCV has changed drastically over the last decade. Historically, pegylated-interferon-a and ribavirin were poorly tolerated and associated with high rates of treatment failure. The discovery of direct-acting antivirals such as sofosbuvir and velpatasvir has increased treatment success rates to 99% (Feld et al., 2015) . Although cost remains a significant barrier, NICE has approved its use in the treatment of chronic HCV infection.
Drug hepatotoxicity
Where drug hepatotoxicity is suspected, the derangement of LFTs must be interpreted in the context of the timing of medication use and change from previous LFTs. Many drugs Box 5. Non-invasive assessment of fibrosis.
ELF test
This is a blood test which measures the serum biomarkers hyaluronic acid, pro-collagen III amino terminal peptide, and tissue inhibitor of metalloproteinase 1 to quantify the degree of fibrosis. Patients with an ELF score > 9.5 are considered to be at high risk of advanced fibrosis.
Fibroscan
Also known as transient elastrography, a probe positioned over the liver transmits a low-frequency wave which propagates through the liver. The velocity of the shear wave is positively correlated to the liver stiffness, a surrogate marker for fibrosis. Patients with a fibroscan score > 7.8 kPa are at high risk of advanced fibrosis.
Box 4. Fibrosis calculators.
Calculators for the assessment of NAFLD are available on GI HEP: http://gihep.com/ FIB4 score ¼
commonly cause an asymptomatic LFT derangement, but clinically significant drug-induced liver injury causing jaundice or impaired liver function is fortunately rare. Medications commonly causing hepatotoxicity include antibiotics (e.g. macrolides, minocycline, nitrofurantoin), sulfonamides, terbinafine, carbamazepine, methyldopa, statins, chlorpromazine, and methotrexate. Further information about specific drugs with associated hepatotoxicity is available on the LiverTox Database (https://livertox.nih.gov/index.html). It is important to also inquire about herbal remedies and recreational drug use.
Typically, drug-induced liver injury develops between 5 days to 3 months of starting a medication, and resolves completely within 2 to 3 months if treatment is promptly stopped (National Institutes of Health, 2017a). The decision to continue, reduce the dose, or discontinue medication is challenging and rests with the individual clinician, who must judge the relevant risks and benefits. Broadly, discontinuation is advised if the patient develops symptoms of liver failure, or when there is a persistent rise in ALT greater than 3 times the upper limit of normal (ULN), or any rise in ALT above 10 times the ULN (National Institues of Health, 2017b).
The approach to deranged LFTs in special patient groups
Abnormal LFTs in pregnancy
Normal pregnancy is associated with physiological changes which affect certain LFTs (Lee and Tran, 2017) . Typically, the ALP is raised, and the serum albumin reduced. Aminotransferases are not affected by normal pregnancy. Some specific conditions affecting LFTs in pregnancy to be aware of include pre-eclampsia, as well as hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome, and intrahepatic cholestasis of pregnancy (Box 6).
Abnormal LFTs in childhood
In children, the standard liver aetiology screen should include the anti-liver kidney microsomal antibody, celiac antibodies, alpha-1-antitrypsin level, and ceruloplasmin if older than 3 years in age (Newsome et al., 2018) . The threshold for referral to hepatology in children should be lower than in adults, due to the wider differential diagnoses.
Challenges with investigating LFTs in primary care
Investigating abnormal LFTs from a primary care perspective is challenging. Although abnormal LFTs are predictive of liver disease (Lilford et al., 2013) , patients with advanced fibrosis warranting hepatology follow-up may be missed due to having normal LFTs and synthetic function (Jarvis and Hanratty, 2017) . Frustratingly, the cause of abnormal LFTs even with an extensive workup was found in only 55% of patients (Armstrong et al., 2012) . The feasibility of the new guidelines must also be considered. Firstly, the ELF test and Fibroscan are not available in primary care in many areas. They are also costly investigations, particularly when repeated every 2 to 5 years, estimated at £108 and £50 respectively each (Jarvis and Hanratty, 2017) . Implications on the volume of work must also be considered. There is no Quality and Outcomes Framework or standardised means of follow-up for liver disease in primary care. Using NAFLD as an example, if the prevalence is 25% of the UK population (NICE, 2016) , and 7.6% of those with NAFLD have advanced fibrosis (Armstrong et al., 2012) , 1 250 000 people would require follow-up from hepatology notwithstanding referrals for other reasons. This is clearly not feasible within the NHS. Hepatologists, GPs, and clinical commissioning groups need to work together to determine realistic guidelines for referral in the context of the local burden of liver disease.
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